Nothing Special   »   [go: up one dir, main page]

Cupisti et al., 2020 - Google Patents

Charcoal for the management of pruritus and uremic toxins in patients with chronic kidney disease

Cupisti et al., 2020

View PDF
Document ID
16613698730865931109
Author
Cupisti A
Piccoli G
Gallieni M
Publication year
Publication venue
Current opinion in nephrology and hypertension

External Links

Snippet

Oral activated charcoal and hemoperfusion can be proposed to patients with severe refractory pruritus based on positive, albeit scattered evidence. They also contribute to reducing uremic toxins. Research on their implementation associated with well established …
Continue reading at iris.unito.it (PDF) (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl group being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/44—Elemental carbon, e.g. charcoal, carbon black

Similar Documents

Publication Publication Date Title
Cupisti et al. Charcoal for the management of pruritus and uremic toxins in patients with chronic kidney disease
Neirynck et al. An update on uremic toxins
Faria et al. Challenges of reducing protein-bound uremic toxin levels in chronic kidney disease and end stage renal disease
Sirich et al. Effect of increasing dietary fiber on plasma levels of colon-derived solutes in hemodialysis patients
Gupta et al. The role of RRT in hyperammonemic patients
Boure et al. Which dialyser membrane to choose?
Dhondt et al. The removal of uremic toxins
Evenepoel et al. Prometheus versus molecular adsorbents recirculating system: comparison of efficiency in two different liver detoxification devices
Meert et al. Prospective evaluation of the change of predialysis protein‐bound uremic solute concentration with postdilution online hemodiafiltration
Florens et al. Using binding competitors of albumin to promote the removal of protein-bound uremic toxins in hemodialysis: hope or pipe dream?
Yamamoto et al. Adsorption of protein-bound uremic toxins using activated carbon through direct hemoperfusion in vitro
Ueda et al. AST‐120, an oral adsorbent, delays the initiation of dialysis in patients with chronic kidney diseases
Li et al. Improved dialysis removal of protein-bound uremic toxins by salvianolic acids
Hanafusa et al. Current uses of dietary therapy for patients with far-advanced CKD
Stadlbauer et al. Artificial liver support systems in the management of complications of cirrhosis
Zhou et al. Efficacy of coupled low-volume plasma exchange with plasma filtration adsorption in treating pigs with acute liver failure: a randomised study
Saar‐Kovrov et al. Reduction of protein‐bound uraemic toxins in plasma of chronic renal failure patients: a systematic review
Takkavatakarn et al. Protein-bound uremic toxin lowering strategies in chronic kidney disease: A systematic review and meta-analysis
Panichi et al. Long term variation of serum levels of uremic toxins in patients treated by post-dilution high volume on-line hemodiafiltration in comparison to standard low-flux bicarbonate dialysis: results from the REDERT study
Tao et al. Enhanced indoxyl sulfate dialyzer clearance with the use of binding competitors
Kjaergaard et al. Preserving residual renal function in dialysis patients: an update on evidence to assist clinical decision making
Tanriover et al. On the importance of the interplay of residual renal function with clinical outcomes in end-stage kidney disease
Labriola et al. Dialysis‐related Amyloidosis: Is It Gone or Should It Be?
Tiranathanagul et al. Comparative efficacy between hemodialysis using super high‐flux dialyzer with hemoperfusion and high‐volume postdilution online hemodiafiltration in removing protein bound and middle molecule uremic toxins: A cross‐over randomized controlled trial
Reis et al. Rationale for a new classification of solutes of interest in chronic kidney disease and hemodialysis